quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:00:00·694d
PRRelease
VBI Vaccines Inc. New logo

VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients

VBIV· VBI Vaccines Inc. New
Health Care
Original source

Companies

  • VBIV
    VBI Vaccines Inc. New
    Health Care

Recent analyst ratings

  • Nov 11UpdateRaymond James$2.00
  • Mar 8UpdateRaymond James$6.00
  • Dec 29UpdateJefferies$6.00

Related

  • SEC629d
    VBI Vaccines Inc. New filed SEC Form 8-K: Bankruptcy or Receivership, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits
  • PR629d
    VBI Vaccines Provides an Update on its Restructuring Proceedings
  • SEC632d
    VBI Vaccines Inc. New filed SEC Form 8-K: Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Other Events
  • PR632d
    VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives
  • SEC667d
    VBI Vaccines Inc. New filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
  • PR667d
    VBI Vaccines Announces Results of Annual General Meeting
  • NEWS694d
    VBI Vaccines Reports New Tumor Response Data From Ongoing Randomized Controlled Phase 2b Study Of VBI-1901 For Patients With Recurrent Glioblastoma
  • SEC694d
    VBI Vaccines Inc. New filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022